USPTO serial 79433896
MUSECELL INNOVATIONS
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- GARCIA, CLAUDIA
- Law office
- TMO LAW OFFICE 111
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MUSECELL INNOVATIONS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Anti-aging cosmetic preparations; anti-aging cream; anti-aging creams; anti-aging creams for cosmetic purposes; anti-aging creams for sun protection for the face and body; anti-aging masks for cosmetic purposes; anti-aging moisturisers; anti-aging moisturizers; anti-aging serums for cosmetic purposes; Non-medicated anti-aging serums for cosmetic use; Non-medicated anti-aging serums for sensitive skin; Non-medicated anti-aging skincare preparations, namely, creams, lotions, gels, toners, cleaners and peels; anti-aging sun protection creams for the face and body. | ACTIVE | — |
| 005 | Cells for medical purposes; cells for medical use; cellular function activating agents for medical purposes; cellulose esters for pharmaceutical purposes; cellulose ethers for pharmaceutical purposes; chemical reagents and chemical preparations for cell separation and cultivation for medical or veterinary purposes; chemical reagents and chemical preparations for separating and cultivating cells for medical or veterinary purposes; living cells for medical purposes; living cells for medical use; pharmaceutical compositions containing stem cells for the treatment of antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases; pharmaceutical preparations containing stem cells for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; pharmaceutical preparations for activating cellular function; stem cells for medical purposes; autoinjectors prefilled with pharmaceutical preparations for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; immunological products, namely, pharmaceutical preparations, for intravenous injections for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; injectable medicinal solutions, namely, pharmaceutical preparations, for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; injectable solutions, namely, pharmaceutical preparations, for medical purposes for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; injectable solutions, namely, pharmaceutical preparations, for use in inhibiting peristalsis for medical purposes; pharmaceutical preparations sold in pre-filled injectors for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; intravenous fluids used for the delivery of pharmaceutical preparations; intravenous solutions for medical purposes used for rehydration, nutrition and the delivery of pharmaceutical preparations; immunosuppressive pharmaceutical preparations; pharmaceutical preparations for the treatment of cystic fibrosis; glycerophosphates for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; pharmaceutical preparations containing phosphates for antibody-treatable, autoimmune, inflammatory, oncological, neurologic, cardiovascular, orthopedic, infectious, gastrointestinal, and genetic diseases and conditions and for treatment of cellular aging; cardiovascular agents for medical purposes; cardiovascular pharmaceutical preparations; cardiovascular pharmaceuticals; cardiovascular preparations; cardiovascular treatment preparations; drugs, namely, pharmaceutical preparations for the treatment of cardiovascular diseases; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations and substances for the prevention of cardiovascular diseases and disorders; pharmaceutical preparations and substances for the treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the prevention of cardiovascular disorders; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations for treating cardiovascular diseases; pharmaceutical preparations for the prevention and treatment of kidney diseases; anti-ulcer agents; pharmaceutical preparations being antiulceratives; pharmaceutical preparations for the treatment of chronic liver diseases. | ACTIVE | — |
| 042 | Analysis of stem cells for medical research; cell culture services for scientific and research purposes, for others; culturing of cells for others for scientific research purposes; research and development in the field of microorganisms and cells; research and development services in the field of microorganisms and cells; research in the field of cell engineering technology; research of induced pluripotent stem cells; scientific laboratory and research services relating to the isolation and cultivation of human tissues and cells; stem cell medical research services; stem cell research services. | ACTIVE | — |
| 044 | Human cell bank services, namely, human stem cell storage services; medical services relating to the removal, treatment and processing of stem cells; stem cell bank services; stem cell therapy services; medical services relating to the removal, treatment and processing of human cells; storage of human cells, namely, human tissue bank services; storage of stem cells, namely, stem cell bank services; providing on-line information relating to the prevention of cardiovascular disease and strokes; medical services relating to the removal, treatment and processing of bone marrow; medical services relating to the removal, treatment and processing of umbilical cord blood; providing information relating to the treatment of cardiovascular and cerebrovascular diseases via the internet; health care services for treating Alzheimer's disease. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 11, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 11, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 15, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 5, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 5, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 21, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 21, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 18, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 17, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 11, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |